Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

Blood

Volumn 131, Issue 11, 2018, Pages 1183-1194

  Herrera, Alex F ^a   Moskowitz, Alison J ^b   Bartlett, Nancy L ^c   Vose, Julie M ^d   Ramchandren, Radhakrishnan ^e   Feldman, Tatyana A ^f   LaCasce, Ann S ^g   Ansell, Stephen M ^h   Moskowitz, Craig H ^b   Fenton, Keenan ⁱ   Ogden, Carol Anne ⁱ   Taft, David ⁱ   Zhang, Qu ⁱ   Kato, Kazunobu ^j   Campbell, Mary ⁱ   Advani, Ranjana H ^k  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e KARMANOS CANCER INSTITUTE   (United States)

^f HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h MAYO CLINIC   (United States)

ⁱ SEATTLE GENETICS INC   (United States)

^j BRISTOL MYERS SQUIBB   (United States)

^k STANFORD UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; BENDAMUSTINE; BLEOMYCIN; BRENTUXIMAB VEDOTIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; INTERFERON; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELPHALAN; NIVOLUMAB; OXALIPLATIN; PREDNISONE; PROCARBAZINE; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRIACYLGLYCEROL LIPASE; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE; VINORELBINE TARTRATE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CHEMOKINE;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE LEVEL; ALOPECIA; ANEMIA; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE SUBPOPULATION; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CHILL; CLASSICAL HODGKIN LYMPHOMA; COLITIS; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; HYPOPHOSPHATEMIA; HYPOXIA; IMMUNOPHENOTYPING; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NOSE OBSTRUCTION; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMABLAST; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; REGULATORY T LYMPHOCYTE; SALVAGE THERAPY; SENSORY NEUROPATHY; T LYMPHOCYTE SUBPOPULATION; THORAX PAIN; THROMBOSIS; TREATMENT RESPONSE; URTICARIA; VOMITING; ADOLESCENT; BLOOD; CLINICAL TRIAL; HODGKIN DISEASE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RECURRENT DISEASE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOKINES; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; NIVOLUMAB; RECURRENCE; T-LYMPHOCYTES, REGULATORY;

EID: 85046084307     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-10-811224     Document Type: Article

References (47)

1. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372(17):1598-1607.
2. Barrington SF, Kirkwood AA, Franceschetto A, et al. PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood. 2016;127(12):1531-1538.
3. Press OW, Li H, Schöder H, et al. US Intergroup trial of response-adapted therapy for Stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816. J Clin Oncol. 2016;34(17): 2020-2027.
4. André MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017;35(16):1786-1794.
5. Straus DJ, Pitcher B, Kostakoglu L, et al. Initial results of US Intergroup trial of response-adapted chemotherapy or chemotherapy/ radiation therapy based on PET for non-bulky stage I and II Hodgkin lymphoma (HL) (CALGB/Alliance 50604) [abstract]. Blood. 2015;126(23). Abstract 578.
6. Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF. Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin’s lymphoma and Hodgkin’s disease. Ann Oncol. 2003; 14(Suppl 1):i11-i16.
7. Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood. 2011;117(16):4208-4217.
8. Perales MA, Ceberio I, Armand P, et al; American Society for Blood and Marrow Transplantation. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21(6):971-983.
9. Josting A, Rudolph C, Reiser M, et al; Participating Centers. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann Oncol. 2002;13(10): 1628-1635.
10. Bartlett NL, Niedzwiecki D, Johnson JL, et al; Cancer Leukemia Group B. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol. 2007;18(6):1071-1079.
11. Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica. 2007;92(1):35-41.
12. Baetz T, Belch A, Couban S, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 2003;14(12):1762-1767.
13. Santoro A, Mazza R, Pulsoni A, et al. Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study. J Clin Oncol. 2016; 34(27):3293-3299.
14. Castagna L, Bramanti S, Balzarotti M, et al. Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. Br J Haematol. 2009;145(3): 369-372.
15. Adams HJ, Kwee TC. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis. Ann Hematol. 2016;95(5): 695-706.
16. Sirohi B, Cunningham D, Powles R, et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann Oncol. 2008;19(7): 1312-1319.
17. Devillier R, Coso D, Castagna L, et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin’s lymphoma responding to prior salvage therapy. Haematologica. 2012; 97(7):1073-1079.
18. Jabbour E, Hosing C, Ayers G, et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer. 2007;109(12): 2481-2489.
19. Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012;119(7):1665-1670.
20. Schmitz N, Pfistner B, Sextro M, et al; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065-2071.
21. Moskowitz AJ, Yahalom J, Kewalramani T, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010;116(23): 4934-4937.
22. Gardai SJ, Epp A, Law C-L. Brentuximab vedotin-mediated immunogenic cell death [abstract]. Cancer Res. 2015;75(15 Suppl). Abstract 2469.
23. Cao A, Heiser R, Law C-L, Gardai SJ. Auristatin-based antibody drug conjugates activate multiple ER stress response pathways resulting in immunogenic cell death and amplified T-cell responses [abstract]. Cancer Res. 2016;76(14 Suppl). Abstract 4914.
24. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012; 30(18):2183-2189.
25. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
26. Roemer MG, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34(23): 2690-2697.
27. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular scle-rosing Hodgkin lymphoma and primary me-diastinal large B-cell lymphoma. Blood. 2010; 116(17):3268-3277.
28. Carey CD, Gusenleitner D, Lipschitz M, et al. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood. 2017;130(22):2420-2430;
29. Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19(13):3462-3473.
30. Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283-1294.
31. Chen R, Palmer JM, Martin P, et al. Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/ refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2015;21(12):2136-2140.
32. Moskowitz AJ, Schöder H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosfamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16(3):284-292.
33. Loge JH, Abrahamsen AF, Ekeberg O, Kaasa S. Reduced health-related quality of life among Hodgkin’s disease survivors: a comparative study with general population norms. Ann Oncol. 1999;10(1):71-77.
34. Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol. 2000;18(3):498-509.
35. Cheson BD, Fisher RI, Barrington SF, et al; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-3068.
36. Biggi A, Gallamini A, Chauvie S, et al. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013;54(5):683-690.
37. Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(10): 1824-1833.
38. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404-413.
39. Collett D. Interval-censored survival data. In: Collett D, ed. Modelling Survival Data in Medical Research. London, United Kingdom: Chapman & Hall; 1994:237-251.
40. Aparicio J, Segura A, Garcerá S, et al. ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann Oncol. 1999;10(5): 593-595.
41. Gutierrez A, Rodriguez J, Martinez-Serra J, et al. Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma. Onco Targets Ther. 2014;7:2093-2100.
42. Garcia-Sanz R, Sureda A, Gonzalez AP, et al. Brentuximab vedotin plus ESHAP (BRESHAP) is a highly effective combination for inducing remission in refractory and relapsed Hodgkin lymphoma patients prior to autologous stem cell transplant: a trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO) [abstract]. Blood. 2016;128(22). Abstract 1109.
43. LaCasce AS, Bociek G, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma [abstract]. Blood. 2015;126(23). Abstract 3982.
44. Hagenbeek A, Zijlstra JM, Lugtenburg P, et al. Transplant BRaVE: combining brentuximab vedotin with DHAP as salvage treatment in relapsed/refractory Hodgkin lymphoma. A phase 1 dose-escalation study. Haematologica. 2016;101(s5):44.
45. Cheson BD, Ansell S, Schwartz L, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128(21):2489-2496.
46. Chen R, Zinzani PL, Fanale MA, et al; KEYNOTE-087. Phase II study of the efficacy and safety of pembrolizumab for relapsed/ refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125-2132.
47. Bartlett NL, Chen R, Fanale MA, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014;7(1):24.